B+
Bull case
20%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-06-10 · RankAlpha Sentiment Codex
CGEM
Cullinan TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-06-10 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-06-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-10
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+23.3
Score
AI commentary
Headline tone is positive but not conviction-high: Q1 results beat the AP/Zacks EPS expectation, and management/SEC updates highlight $393.3m cash with runway into 2029 plus multiple 2026 catalysts. Still, coverage is thin, there is no analyst revision signal, and the tape remains dominated by binary clinical/regulatory risk rather than commercial traction.
RankAlpha Sentiment Codex - 2026-06-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-06eventCLN-978 initial SLE/RA data and biomarker follow-throughHigh impact
June 2026 EULAR readout and the June 8 8-K point to early safety, B-cell depletion, biomarker, and preliminary activity data in SLE/RA; the filing said all lab markers of disease activity improved in patients with clinically significant baseline abnormalities, which is supportive but still early [#SEC-8K-2026-05-07] [#8-K-2026-06-08].
2026-09-30eventCLN-978 follow-on multi-dose RA and SjD data through 2H 2026High impact
Management still expects follow-on CLN-978 data in Q3 2026 for RA and Q4 2026 for SjD; durability of B-cell depletion and any clinical activity will matter more than the first-dose signal [#SEC-8K-2026-03-10] [#SEC-8K-2026-05-07].
2026-12-31catalystCLN-049 AML/MDS expansion and registrational pathHigh impact
Cullinan still expects to advance CLN-049 with additional AML data and expansion work in 2026; this is a longer-horizon thesis driver, but it remains early and needs sustained efficacy and tolerability to support a registrational path [#SEC-8K-2026-03-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-10 • Updated nightlySource: Internal modelMethodology